To read more on these records and others in the pharmaceutical arena, please visit Clarivate Analytics Cortellis, where you may access full pdf documents of the same, along with expert analysis and indexing of their content to accompany detailing of such aspects as expirations, infringements, licensing and exclusivity.

The Patent Gazette provides snapshot analysis and indexing of pharmaceutically relevant patenting within days of its publication by patent offices. Primarily focusing on material from the main three patents offices (i.e., the EPO, USPTO, and WIPO), it provides brief descriptions of a patent’s content and seeks to link it to both prior patenting of relevance and to any commercial activity pertinent to the technology being described.

Subscription and access to Cortellis may be tailored and restricted to particular subject areas of interest, such as only its patenting content. For more details please do contact us.


WO2019215767-A1: “Inhaler device.”

Assignee: Pharmadevices srl

Inventors: Mercandelli, Alberto

IPC Codes: A61M 15/00

Publication Date: 14-Nov-2019

Earliest Priority Details: WO2018IT66, 09-May-2018

The application describes a dry powder inhaler configured to take one or more capsules. It is disclosed that the inhaler can be loaded (figs 2, 2a and 2b) and left without breaking the capsule until immediately before use. It is also disclosed that the pulling apart of the capsule results in two pieces being retained inside the inhaler rather than fragments being created which could be drawn into the patient's lungs. In figs 2c,2d, the inhaler is opened (cover 70) and slider 36 moved from left to right immediately before use. Moving the slider causes capsule 2 to be fractured perpendicular to its length (figs 3, 3a).

This appears to be the first application from either the inventor or the applicant.

Mercandelli appears to be on the staff of MG2 srl, a maker of automatic machines for the food, cosmetics and pharmaceutical industry. It was founded in 1966 and appears to specialize in filling hard shell capsules for the pharmaceutical industry. MG2 appears not to have filed any patent applications on inhalers.


WO-2019215235 A2: “Bi-dose nasal spray.”

Assignee: Akroswiss AG

Inventors: Fröhlich, Johannes Malta; Zadory, Matthias Gergely; Biendl, Stefan Pascal

IPC Codes: A61M 15/08; A61M 15/00; A61M 11/00

Publication Date: 14-Nov-2019

Earliest Priority Details: CH2018575, 08-May-2018

The application describes a nasal administration device which administers two sprays each with an equivalent, defined volume of solution and which can operate effectively irrespective of the orientation of the device, and hence the patient. The device appears to be particularly intended for the administration of sedatives and anticonvulsants, especially midazolam.

This appears to be the first application from the present team, but it has already appeared as CH714774B1. See also Eur Radiol Exp 2019 Dec; 3; 32 ‘In vitro qualitative and quantitative CT assessment of iodinated aerosol deposition using a 3D-printed nasal replica’ listing the team as authors but showing them affiliated to KlusLab Research.


WO2019217820-A1: “Devices and systems for delivery of combination therapies.”

Assignee: Bristol-Myers Squibb Company

Inventors: Mcloughlin, Martin, John; Zieminski, Stephen, Lawrence; Larrow, Chester; Mumpower, Mariano

IPC Codes: A61J 1/20; A61J 3/00; A61M 5/14

Publication Date: 14-Nov-2019

Earliest Priority Details: US2018670266, 11-May-2018

Three co-published applications (WO2019217820, '845 and '864) describe two different ways of administering a combination of liquid drugs. In one, a portable cannister containing up to three different drugs, all held in their own vials and linked through to a single infusion line, is described. The drug combination is administered under pressure. In the other two applications, a bar onto which several cases may be clipped is described. Each case contains a single drug and fluid connection between the drug and the bar is made when the case is inserted into it. The drugs mix in the bar and are delivered via a cannula to the patient. In both cases the applications are intended to reduce the possibility of needle stick injury to an operator and the amount of drug wasted.

The applications appear to be the first from the team, two of whom appear to be associated with keytech, a design, development and engineering organization, specializing in medical products especially drug delivery devices. It is headquartered in Baltimore, USA.


WO2019215471-A1: “Handheld metered dose inhaler.”

Assignee: Biocorp Production SA

Inventors: Marcoz, Alain; Pereira, Alexandre; Pollard, Mathieu

IPC Codes: A61M 15/00

Publication Date: 14-Nov-2019

Earliest Priority Details: WO2018IB685, 11-May-2018

The application describes a metered dose inhaler (MDI) with a visual cue of the number of doses remaining/used and with a removable data processing system which can measure the drug administered and correlate it with the released doses. This appears to be the first application from the company on an MDI and continues the company's interests in smart inhalation technology.

In 2016 the company launched Inspair, an add-on for any MDI which would monitor the usage of the MDI, link to a smart device and provide guidance on the correct usage of the MDI.

Biocorp was founded in 2004 in Issoire, France and specializes in the development and manufacturing of smart medical devices and drug delivery systems.


WO2019215273-A1: “Devices and methods for determining particle concentration in a sample.”

Assignee: F. Hoffmann-La Roche AG; Roche Diagnostics GmbH; Roche Molecular Systems, Inc.; Sandstone Diagnostics, Inc.

Inventors: Epperson, Jon; Fredriksen, Laura; Hong, Kyungjin; Li, Jenq-Thun; Parikh, Bhairavi, Rajiv; Schaff, Ulrich

IPC Codes: G01N 33/543; G01N 33/569

Publication Date: 14-Nov-2019

Earliest Priority Details: US2018669357, 09-May-2018

The application describes a cartridge for use with Sandstone's centrifuge system. The cartridge is designed to take a sample of blood and separate target cells (eg bacteria cells) from the other components of the sample. The target cells will be separated so that they come into contact with an imaging surface where they can be quantitated optically. The process appears to be targeted towards the detection of sepsis.

Presently Sandstone offers the Torq system designed to separate plasma from a blood sample, and the FDA-approved Trak male fertility test.

In January 2018 the company announced the closing of $5.8 million in Series A1 funding. This appears to be the first application from Roche and Sandstone.

Sandstone Diagnostics was founded in 2012 initially to improve men's reproductive health.


WO2019215149-A1: “Device for packaging and dispensing a product, with vial and dispensing mouthpiece equipped with a filter.”

Assignee: Horus Pharma; Santen SA

Inventors: Pozzi, Jacques

IPC Codes: B65D 47/18; B65D 47/32; A61F 9/00

Publication Date: 14-Nov-2019

Earliest Priority Details: FR2018464, 07-May-2018

Two co-published applications (WO2019215149, '150) describe different eyedrop dispensers. Both appear designed to dispense a carefully controlled volume of liquid by guiding the liquid to be dispensed into a small chamber immediately before its administration. Both dispensers are also designed to reduce the chances of bacterial contamination entering the dispensers during use. They are both disclosed as being suitable for use with eyedrops formulated without preservative. Both applicants offer such formulations.

This appears to be the first joint filing from Horus and Santen, and the inventor appears based at Sivel.


WO2019215719-A1: “Nebulizers, nebulizer cartridges and uses thereof.”

Assignee: Omega Life Science Ltd

Inventors: Hazani, Miron

IPC Codes: A61J 7/00; A61K 9/00; A61M 15/00

Publication Date: 14-Nov-2019

Earliest Priority Details: US2018668263, 08-May-2018

The application describes a nebulizer which comprises a porous medium from which the drug solution to be administered is nebulized. This porous medium needs periodic refreshment with drug solution and the present application describes a method of conveying the drug solution from the reservoir to the porous medium. This system is disclosed to produce droplets with a mean diameter of less than 5 micron. It also appears to be particularly targeted towards the delivery of salbutamol, and to be in support of the company's Alphazer nebulizer.

The application continues from WO2016181390 on nebulizers and their use.

Omega Life Science was established in 2011 and is a subsidiary of the Nanosol Group.


US20190343765-A1: “Single-walled carbon nanotube-assisted antibiotic delivery and imaging techniques.”

Assignee: Texas Christian University

Inventors: Naumov Anton V

IPC Codes: A61K 9/00; A61K 31/43; A61P 31/04; A61K 31/65

Publication Date: 14-Nov-2019

Earliest Priority Details: US2018670949, 14-May-2018

The application describes the use of antibiotics, especially methicillin or doxycycline, adhered to carbon nanotubes for the treatment of bacterial infections. Initial findings show that the combination is more effective than the corresponding antibiotic alone.

This appears to be the first filing from the inventor on the use of carbon nantubes in this area. Naumov is Assistant Professor at the University. His interests include nanotechnology and the use of nanomaterials in medicine.


WO2019215173-A1: “Inhaler.”

Assignee: Societe Industrielle de Sonceboz SA

Inventors: Trummer, Herbert; Bailo, Nicolas; Pajot, Olivier; Tilloy, Denis; Verez, Guillaume

IPC Codes: A61M 15/00

Publication Date: 14-Nov-2019

Earliest Priority Details: EP2018171361, 08-May-2018

The application describes an inhaler for use with dry powder capsules. The pump in the inhaler which is used to propel the drug powder to the patient is stated to be capable of operating at a flow rate of greater than 30 litres per minute. This is also stated to be advantageous when used by patients who have limited breathing capacity.

This appears to be the first application from the team, and to be the first application from the applicant on inhalers.


WO2019213768-A1: “Apparatus for metering and dispensing viscous substance.”

Assignee: Acasti Pharma Inc

Inventors: Lemieux, Pierre; Despins, Simon; Aziz, Sarya; Bissuel, Nicolas; Lemieux, François

IPC Codes: G01F 11/04; A61J 3/07

Publication Date: 14-Nov-2019

Earliest Priority Details: US2018669431, 10-May-2018

The application describes an apparatus for the dispensing of predetermined amounts of a viscous fluid into capsules. The apparatus and its use appear to be particularly directed towards reducing the formation of bubbles during the filling. The application discloses that the fluid may be krill oil.

The company is developing CaPre, a krill oil mixture in phase III trials for the treatment of hypertriglyceridemia. It is intended to be supplied in capsules. The company is pursuing the development and/or distribution partnerships for CaPre.

This appears to be the first application from the company directed towards methods and apparatus for filling capsules.

No Comments